News & Events

Recently, on the latest issue of CARDIOLOGY 2.0, an authoritative international journal of cardiac imaging, the editors listened to the opinions of leaders in the field of cardiac imaging around the world and selected 25 companies with the most core leadership in the discipline. Among them, the Novasight Hybrid System intracardiac ultrasound imaging two in one equipment produced by Conavi, a Canadian medical device company, which is an investment enterprise of Zhongguancun Dahe Capital CCAA, has been recognized by relevant experts with its core patents, internationally leading finalized products and significant clinical application value, and has been shortlisted together with international well-known enterprises such as General Electronics, Siemens, Philips, etc, It won the honorary title of “Top 25 Image Technology Leaders in 2020” in the authoritative journal CARDIOLOGY 2.0.

Conavi Medical is an advanced medical device company focusing on the research and development of minimally invasive surgical imaging technology. The company has two star products: Novasight Hybrid System dual-mode imaging system and Foresight ICE System intracardiac echocardiography system. These two imaging products have the advantages of low cost and high image quality, which can greatly improve the success rate of surgery, reduce the probability of surgical complications and the mortality of some interventional operations, so as to protect the safety of minimally invasive surgery.

The editorial office of CARDIOLOGY 2.0 magazine is located on the Fifth Avenue of New York. Its editorial members include James Thomas, doctoral supervisor of Northwestern Medical University, and other world-renowned cardiovascular leaders. John Matthews, editor in chief of the magazine, said when introducing the selection: “Cardiovascular (invasive and non-invasive) The development of imaging equipment is very fast. In this selection, we selected the most successful and revolutionary 25 intracardiac imaging companies. These ‘leaders’ will really influence the subject of intracardiac imaging in the future. They will use artificial intelligence, learning algorithms, 3D image rendering and other methods to change the visualization of doctors’ real-time operations. “

When Dr. Gergana Koleva, an international authority on cardiac imaging, introduced Novasight, Comments like this: “As open coronary artery surgery is becoming more and more rare, the competition for innovative technologies is becoming increasingly fierce, and these new technologies require excellent visualization capabilities in minimally invasive surgery. The Novasight Hybrid System intracardiac ultrasound imaging two in one device produced by Conavi Company combines OCT and IVUS, two conventional imaging methods, into one device with superior capabilities, which is expected to completely change the future of angioplasty.”

It is worth mentioning that Novasight was included in the “green channel” of the special approval procedure by the Medical Device Technical Evaluation Center (CMDE) of the State Drug Administration in 2019 because of its innovation. In the past February, the product has officially passed the medical device registration approval and listing in Japan after obtaining the listing license from the FDA of the United States and HealthCanada of Canada.

In the opinion of insiders, with the continuous improvement of medical technology, high-end medical devices are expected to help precision medicine and become the next outlet. Novasight accelerated its listing in mature pharmaceutical markets such as Europe, America and Japan, which is expected to boost its commercialization in the Greater China market.

Note: This article was first published by Conavi’s partner Yuanda Medical. In 2017, Yuanda Pharmaceutical signed a strategic agreement with Conavi Canada and obtained the exclusive agency rights of its “Foresight ICE” and “Novasight Hybrid” products in Chinese Mainland, Hong Kong, Macao, Taiwan and other regions. Yuanda Medical said in the article that Conavi’s series of products not only improved the international product line of Yuanda’s high-end medical equipment sector, but also will become a new profit growth point of the company.